Aeterna Zentaris will present at

Live videowebcast eo on Wednesday June 15e at 12:30 p.m. ET

TORONTO, ONTARIO, June 09, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced Dr. Klaus Paulini, Chief from the management of Aeterna Zentaris will present at the JMP Securities Life Sciences Conference on Wednesday, June 15, 2022 at 12:30 p.m. ET to be held in New York, New York.

In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community registered to attend the conference. For more information, please visit the conference website.

A live video webcast of the presentation will be available on the Company’s website on the Events page of the Investors section of the Company’s website ( The webcast replay will be archived for 90 days after the event.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company that develops and markets a diverse portfolio of pharmaceutical and diagnostic products focused on areas of high unmet medical need. The Company’s lead product, macimorelin (Macrilen; Ghryvelin®), is the first and only oral test approved by the US FDA and the European Commission indicated for the diagnosis of Adult Growth Hormone Deficiency (AGHD). The Company is building on the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood growth hormone deficiency (CGHD), an area of ​​significant unmet need, in collaboration with Novo Nordisk.

Aeterna Zentaris is dedicated to the development of therapeutic assets and has recently taken steps to establish a growing preclinical pipeline to potentially address unmet medical needs in a number of indications, including neuromyelitis optica spectrum disorder ( NMOSD), Parkinson’s disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS; Lou Gehrig’s disease). Additionally, the Company is developing an oral prophylactic bacterial vaccine against SARS-CoV-2 (COVID-19) and Chlamydia trachomatis.

For more information, visit and connect with the company on Twitter, LinkedIn and Facebook.

Investor contacts:

jenene thomas
T (US): +1 (833) 475-8247
E : [email protected]


Comments are closed.